https://bio.nikkeibp.co.jp/atcl/news/p1/25/09/24/13768/

MabGenesis, a developer of antibody drugs for humans and animals, and Nippon Soda have signed a collaborative research agreement to develop monoclonal antibody drugs for dogs and cats.

MabGenesis has antibody libraries for dogs, cats, and camels. Its unique features include its proprietary phage display antibody library construction technology. Under the agreement, MabGenesis will utilize its antibody library to search for and acquire antibodies and provide them to Nippon Soda. Nippon Soda will develop a process for stable production of the antibodies and commercialize them. Target disease, target antigen, and future development schedule have not been disclosed.

Nippon Soda is a company involved in pesticide research and development and the manufacture of pharmaceutical ingredients.